Phrontline Biopharma is based in Shanghai, China. It has raised $68M in total funding. Latest round: Pre-A+.
Phrontline Biopharma funding overview
Phrontline Biopharma is based in Shanghai, China. Phrontline Biopharma has raised $68M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Pre-A+ announced in November 2025. The round record for Phrontline Biopharma runs through 2025; nothing later has been disclosed. Investors on record include Lapam Investment, Samsung Venture Investment Corporation (SVIC), Guofang Innovation, Hankang Venture Capital, Songqing Capital, Jifeng Ventures and 4 others. 10 distinct backers are named across the disclosed rounds.
Frequently asked about Phrontline Biopharma funding
How much has Phrontline Biopharma raised?
Phrontline Biopharma has raised $68M in total disclosed funding across the rounds on record.
Who has invested in Phrontline Biopharma?
Lapam Investment, Samsung Venture Investment Corporation (SVIC), Guofang Innovation, Hankang Venture Capital, Songqing Capital, Jifeng Ventures are named among the investors backing Phrontline Biopharma.
What was the latest Phrontline Biopharma funding round?
The most recent disclosed round is a Pre-A+, announced in November 2025.
Where is Phrontline Biopharma based?
Phrontline Biopharma is based in Shanghai, China.
When did Phrontline Biopharma last raise?
The last disclosed Phrontline Biopharma round closed in November 2025 at Pre-A+.
Round data for Phrontline Biopharma is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Shanghai and backer lists below.
